The nonpartisan Congressional Price range Workplace projected that because of the negotiations, Medicare’s costs for semaglutide merchandise “will fall considerably starting in 2027.”
That may additionally open the door to decrease costs for competing weight problems medication like Eli Lilly’s Zepbound. Pharmacy profit managers, which negotiate drug costs, would have extra leverage to demand decrease costs nearer to what the federal government pays for semaglutide. If the federal government had been to increase protection of weight problems medication, the quantity Medicare would spend on every affected person taking one in every of them would fall by a few third in 2027, the C.B.O. projected.
That may gradual the expansion of the federal government’s spending on weight problems medication whilst extra folks on Medicare began utilizing them.
New costs for the ten medication within the first spherical of worth negotiations had been introduced final summer season. These costs will go into impact subsequent 12 months.
Drugmakers had been relieved that these cuts weren’t deeper.
Medicine Chosen for Medicare’s Second Spherical of Value Negotiations
Costs will go into impact in 2027.
1. Ozempic, Rybelsus and Wegovy, for diabetes and weight problems
2. Trelegy Ellipta, for lung circumstances
3. Xtandi, for prostate most cancers
4. Pomalyst, for blood most cancers
5. Ibrance, for breast most cancers
6. Ofev, for lung circumstances
7. Linzess, for gastrointestinal circumstances
8. Calquence, for blood cancers
9. Austedo and Austedo XR, for neurological ailments
10. Breo Ellipta, for lung circumstances
11. Tradjenta, for diabetes
12. Xifaxan, for liver and gastrointestinal issues
13. Vraylar, for melancholy
14. Janumet and Janumet XR, for diabetes
15. Otezla, for inflammatory circumstances
:max_bytes(150000):strip_icc()/Health-GettyImages-1500717013-55fe4215d03a41e7b6de916b9afe1f37.jpg "Normal Blood Pressure for Women Depending on Age")
